The latest version of Keytruda could eventually capture between 30% and 40% of the market for the original, Merck CEO Rob Davis said at the JPMorgan Healthcare Conference in San Francisco on Monday.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... but I recognize we’ll know at the JPMorgan Healthcare Conference.” Overall, MRK ranks 6th on our list of ...

JPMorgan upgraded Wuxi Biologics (WXXWY ... Although the newsthat WuXi Bio sold its Ireland vaccine facility to Merck (MRK) for about $500M sent the stock lower, the firm thinks the company ...